Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling (Q40200583)

18 September 2017

title

Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling (English)

1 reference

18 September 2017

Shimanuki T

1

1 reference

18 September 2017

Hara T

2

1 reference

18 September 2017

Furuya T

3

1 reference

18 September 2017

Imamura T

4

1 reference

18 September 2017

Miyazono K

5

1 reference

18 September 2017

language of work or name

English

0 references

publication date

4 December 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

26

1 reference

18 September 2017

issue

23

1 reference

18 September 2017

page(s)

3311-3320

1 reference

Structure of the ternary signaling complex of a TGF-beta superfamily member

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Identification of a functional binding site for activin on the type I receptor ALK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Morin inhibits 12-O-tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Smad6 inhibits signalling by the TGF-beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Crystal structure of the BMP-2-BRIA ectodomain complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Betaglycan presents ligand to the TGF beta signaling receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Two major Smad pathways in TGF-beta superfamily signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Efficient selection for high-expression transfectants with a novel eukaryotic vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Interaction of Drosophila inhibitors of apoptosis with thick veins, a type I serine/threonine kinase receptor for decapentaplegic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

An unusual feature revealed by the crystal structure at 2.2 A resolution of human transforming growth factor-beta 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

inferred from DOI database lookup

7 January 2021

based on heuristic

Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

inferred from DOI database lookup

7 January 2021

based on heuristic

Distinct functional domains of TGF-beta bind receptors on endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210123

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1210123

1 reference

Dimensions Publication ID

18 September 2017

1001441453

0 references

1 reference